Genetic Technologies (GENE) has released an update.
Genetic Technologies Limited announces the global launch of its geneType™ Risk Assessment portfolio on its proprietary EasyDNA platform, now accessible in 42 countries. This strategic move aims to boost the company’s annual revenue beyond the current A$7.5 million, while significantly reducing monthly cash burn and driving towards profitability. The initiative, backed by influential partnerships and a focus on personalized healthcare, will streamline genetic testing processes and expand consumer access to its risk assessment tests for serious diseases.
For further insights into GENE stock, check out TipRanks’ Stock Analysis page.
